191423 Advance Market Commitments for promoting research and development on neglected diseases

Wednesday, October 29, 2008: 10:30 AM

Michael Kremer, PhD , Dept of Economics, Economics Department, Harvard University, Cambridge, MA
Italy, the UK, Canada, Norway, Russia, and the Bill and Melinda Gates Foundation recently committed $1.5 billion for a pilot Advance Market Commitment (AMC) for pneumococcus vaccine. Under such Advance Market Commitments donors pledge to help finance the purchase of suitable products for use in developing countries if and when they are developed. This talk will discuss the potential of AMCs to stimulate R&D on neglected diseases and improve access, and the differing roles of AMCs for early-stage products and late-stage products, such as pneumococcus. It will examine the advantages and disadvantages of AM Cs relative to other ways of promoting research and discuss when advance market commitments are likely to be appropriate. Finally, it will discuss some of the practical issues in AMC design.

Learning Objectives:
Understand potential role of Advance Market Commitments (AMCs) in encouraging research and development and promoting access. Understand trade-offs around design issues on AMCs.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: of research I have done and publications written on the economics of research and development of vaccines.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

See more of: Philanthropic Partnerships for Public Health
See more of: APHA-Special Sessions